By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NicOx SA 

1900 Route des CrĂȘtes, BP 313

Sophia-Antipolis  Cedex  06906  France
Phone: 33-0-4-92387020 Fax: 33-0-4-92387030


Drug Discovery


Merck & Co.  Nitric oxide-donating compounds

Company News
NicOx SA (COX.PA) Announces The Presentation Of NCX 667 Scientific Data At AOPT 2017 2/21/2017 11:01:34 AM
NicOx SA (COX.PA) Transfers Commercial Operations to New Company, Gets Minority Stake 7/5/2016 6:52:52 AM
FDA Grants Priority Review For NicOx SA (COX.PA)'s AC-170 New Drug Application 6/21/2016 8:16:20 AM
NicOx SA (COX.PA) Submits New Drug Application For AC-170 To U.S. FDA 4/20/2016 9:45:36 AM
Bausch & Lomb And NicOx SA (COX.PA) Announce FDA Acceptance Of New Drug Application For Novel Glaucoma Candidate VESNEO (Latanoprostene Bunod) 9/22/2015 11:15:26 AM
NicOx SA (COX.PA) Gets Boost From Strong Prospects For Glaucoma Drug Vesneo 9/25/2014 6:25:39 AM
NicOx SA (COX.PA) Focuses U S. Operations On National Launches Of Sjo™ And Retnagene™ And Restructures RPS® Licensing Agreement 7/10/2014 6:03:19 AM
NicOx SA (COX.PA) Scoops Up Aciex Therapeutics In $120 Million Deal 7/2/2014 7:13:20 AM
NicOx SA (COX.PA) Launches Commercial Operations In Germany 6/30/2014 8:13:01 AM
NicOx SA (COX.PA) And Sequenom Inc. (SQNM) Announce The Launch Of Expanded Access To Retnagene™ Test Portfolio In The U.S. 6/19/2014 8:55:25 AM